抗凝治疗在血栓栓塞性疾病，如外周动脉疾病、深静脉血栓形成和缺血性脑卒中等的治疗中发挥重要作用。血浆纤维蛋白原参与形成动脉血栓和静脉血栓，血浆纤维蛋白原水平还与血液的黏滞度有关。由蛇毒制成的降纤维蛋白原类药物虽然没有直接的抗凝、溶栓作用，但通过降低血浆纤维蛋白原的水平，有助于干预血栓形成、降低血黏度、改善血流量。

Clinical effects of defibrinogenating enzymes in the treatment of thromboembolism diseases        LI Xiao-xi.Department of Vascular-thyroid-breast Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Abstract    Antithrombotic therapy plays an important role in the treatment of thromboembolism diseases, such as peripheral arterial disease, deep vein thrombosis and acute ischemic stroke. Plasma fibrinogen is known to play an important role in the pathogenesis of venous and arterial thromboembolism, and is one of the main determinants of blood viscosity. Defibrinogenating enzyme, purified fraction derived from the venom, does not directly affect any other coagulation factors or hematological components.  Defibrinogenation agents reduce rapid fibrinogen concentrations, produces anticoagulation by depleting the substrate needed for thrombus formation. Depletion of fibrinogen also decreases blood viscosity, resulting in improved blood circulation.